WASHINGTON, Aug 18 (Reuters) - Concordia Pharmaceuticals Inc
and Par Pharmaceutical Inc have settled charges they unlawfully
agreed not to compete in the sale of a generic version of
Kapvay, a drug used to treat attention deficit hyperactivity
disorder, the U.S. Federal Trade Commission said on Tuesday.
The FTC had alleged Concordia, a unit of Concordia
Healthcare Corp CXR.TO , had agreed not to sell a generic
version of the drug in exchange for a share of Par's revenues.
Par is a subsidiary of Par Pharmaceutical Holdings Inc. PRX.N .
Concordia and Par were the only two firms permitted by U.S.
regulators to sell a generic version of Kapvay. The settlement
bars them from enforcing anticompetitive provisions of their
agreement, including the profit-sharing provision, the FTC said.